Key result
The Nobori biolimus-eluting stent is reviewed based on current available data from pharmacokinetic, observational, and randomized clinical trials.
Why the study?
Does the Nobori biolimus-eluting stent improve outcomes compared to other drug-eluting stents in patients undergoing percutaneous coronary intervention?
Does the Nobori biolimus-eluting stent improve outcomes compared to other drug-eluting stents in patients undergoing percutaneous coronary intervention?
This review summarizes the available evidence from pharmacokinetic, observational, and randomized clinical trials on the Nobori biolimus-eluting stent.
Current Nobori evidence insufficient to guide PCI stent choice; leaves open need for updated head-to-head RCTs.
Despite first-generation drug-eluting stents (DES) dramatically reduced the need for repeat revascularization in patients undergoing percutaneous coronary intervention, their use was associated with an increased risk of thrombotic events at long-term follow-up. The Nobori biolimus-eluting stent (BES) is a second-generation DES with a biodegradable poly-lactic acid polymer. During the last few years, several randomized trials have compared the Nobori BES with other DES, making this device the most investigated biodegradable DES. In this article, we reviewed current available data about Nobori BES from pharmacokinetic and observational studies to randomized clinical trials.
No takes yet. Share an insight, caveat, or question.
Piccolo et al. (2014) conducted a review in Percutaneous coronary intervention. Nobori biolimus-eluting stent (BES) vs. Other drug-eluting stents was evaluated. The Nobori biolimus-eluting stent is reviewed based on current available data from pharmacokinetic, observational, and randomized clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: